JP2023550666A5 - - Google Patents

Info

Publication number
JP2023550666A5
JP2023550666A5 JP2022559909A JP2022559909A JP2023550666A5 JP 2023550666 A5 JP2023550666 A5 JP 2023550666A5 JP 2022559909 A JP2022559909 A JP 2022559909A JP 2022559909 A JP2022559909 A JP 2022559909A JP 2023550666 A5 JP2023550666 A5 JP 2023550666A5
Authority
JP
Japan
Prior art keywords
seq
group
antigen
combination
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025174 external-priority patent/WO2021202734A2/en
Publication of JP2023550666A publication Critical patent/JP2023550666A/ja
Publication of JP2023550666A5 publication Critical patent/JP2023550666A5/ja
Pending legal-status Critical Current

Links

JP2022559909A 2020-03-31 2021-03-31 ヌクレオシド修飾ｍＲＮＡを使用する汎用インフルエンザワクチン Pending JP2023550666A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063002682P 2020-03-31 2020-03-31
US63/002,682 2020-03-31
PCT/US2021/025174 WO2021202734A2 (en) 2020-03-31 2021-03-31 Universal influenza vaccine using nucleoside-modifield mrna

Publications (2)

Publication Number Publication Date
JP2023550666A JP2023550666A (ja) 2023-12-05
JP2023550666A5 true JP2023550666A5 (https=) 2024-04-10

Family

ID=77929131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559909A Pending JP2023550666A (ja) 2020-03-31 2021-03-31 ヌクレオシド修飾ｍＲＮＡを使用する汎用インフルエンザワクチン

Country Status (9)

Country Link
US (1) US20230181715A1 (https=)
EP (1) EP4126032A4 (https=)
JP (1) JP2023550666A (https=)
KR (1) KR20230104068A (https=)
CN (1) CN116583296A (https=)
AU (1) AU2021246064A1 (https=)
CA (1) CA3178344A1 (https=)
MX (1) MX2022012251A (https=)
WO (1) WO2021202734A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CN117534737B (zh) * 2022-07-15 2024-09-06 中山大学·深圳 一种季节性甲型流感通用Mosaic重组抗原及其疫苗和应用
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
CN118256522A (zh) * 2022-12-19 2024-06-28 斯微(上海)生物科技股份有限公司 一种广谱流感mRNA疫苗
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2358386B1 (en) * 2008-11-28 2016-11-02 Statens Serum Institut Optimized influenza vaccines
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
AU2016253972B2 (en) * 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
JP7384512B2 (ja) * 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
US20190274968A1 (en) * 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
MA46766A (fr) * 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
CA3086456A1 (en) * 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof

Similar Documents

Publication Publication Date Title
JP2023550666A5 (https=)
Deng et al. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
JP2023088962A (ja) インフルエンザウイルスワクチン及びその使用
CN102257135B (zh) 流感疫苗的生产
JP2023530229A5 (https=)
Nobusawa et al. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses
Stevens et al. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity
US8828406B2 (en) Influenza viruses and uses thereof
US9849172B2 (en) Influenza virus vaccines and uses thereof
US20210260179A1 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN103269715B (zh) 用于改进流感病毒和疫苗种子的生产的方法
JP7654625B2 (ja) タンパク質加水分解標的ウイルス、その生ワクチン及びその作製方法と用途
Kwon et al. An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells
JP2014504500A5 (https=)
JP2023550600A5 (https=)
CN102939096A (zh) 用于预防和治疗流感病毒疾病的疫苗
Levina et al. Nanoparticle-mediated nonviral DNA delivery for effective inhibition of influenza A viruses in cells
WO2011029914A1 (en) Method for the preparation of an influenza virus
WO2016205347A1 (en) Influenza virus vaccines and uses thereof
CN119947747A (zh) 流感病毒疫苗
Sia et al. Engineered nanoparticle applications for recombinant influenza vaccines
US12133888B2 (en) Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
Zavyalova et al. Aptamers to hemagglutinin: A novel tool for influenza virus recognition and neutralization
Xiong et al. Influenza virus genomic mutations, host barrier and cross-species transmission
Li et al. Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene